IMMUNE RESPONSE mit heiler AdHoc!!!!Hier der Text! - 500 Beiträge pro Seite

[Schnelle]

Monday March 6, 7:00 am Eastern Time

Company Press Release

SOURCE: The Immune Response Corporation

The Immune Response Corporation Announces
REMUNE(TM) Appears to Stimulate Broad Cross Reactive Immune
Responses to Several Different Strains Of HIV & The Patient`s Own Virus

REMUNE Shows Promise as a Universal Immunogen, Stimulates Both Killer And Helper T Cell
Activity

CARLSBAD, Calif., March 6 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced
today the presentation of new data appearing to demonstrate that people infected with HIV-1 who are treated with
REMUNE(TM) (an immune-based therapy consisting of whole inactivated HIV-1 virus depleted of its gp120 coat protein),
and haart (highly active antiretroviral therapy), can recognize and mount an immune response to their own HIV virus. ``Patients
treated with REMUNE in an open label research study at the San Diego Naval Medical Center, appeared to mount strong
CD4 T helper cell proliferative responses to their own virus,`` Dr. Ronald Moss, VP of Medical and Scientific Affairs at the
Company, told fellow scientists at the recent UCLA 2000 Symposium on HIV/AIDS in Palm Springs, CA. ``Normally, CD4 T
helper cell proliferation is tested only against laboratory strains of the virus. The response to a laboratory strain, however, may
not predict patients` ability to fight the strain with which they are infected. The fact that the patients` CD4 T helper cells
appeared to be able to mount an immune response to their own as well as laboratory strains of HIV-1 also suggests that the
immune response is directed at conserved regions of the virus and is cross-reactive.``

To test whether REMUNE shows promise as a universal immunogen, the Company`s scientists studied the proliferative
response to various strains (or clades) of the HIV-1 virus found throughout the world. The speed with which outside, or
``coat``, regions of the HIV-1 virus mutate has been a key obstacle to developing effective therapeutic vaccines against HIV,
and different strains of HIV-1 have emerged due to mutations in the outside of the virus. The data presented by Dr. Moss show
that REMUNE treated patients showed proliferative responses to several strains of the HIV-1 virus, including clade B (U.S.
and Europe), clade E (Asia) and clade C (which is considered to be the most common subtype of HIV-1 worldwide and is
prevalent in Africa and Asia). This suggests that REMUNE stimulates CD4 cells to recognize conserved inside, or ``core``,
regions of the virus, which do not mutate as rapidly. REMUNE may therefore potentially serve as a universal immunogen. ``Our
recently issued patents further strengthen our intellectual property position for the development of products for both the
treatment and prevention of HIV disease,`` said Dennis J. Carlo, Ph.D., President and CEO of The Immune Response
Corporation.

Dr. Moss also presented data showing that a response of CD8 T ``killer`` cells, which can destroy HIV-infected cells, was
evident in REMUNE-treated patients. This is especially promising since CD8 cell activity has been shown by some researchers
to decrease with potent antiviral drugs. In REMUNE treated patients, the levels of perforin and the chemokine MIP-1 Beta,
which are two major markers for CD8 cell activity, increased post-treatment. ``These data are consistent with other data which
suggest that CD4 T helper cells provide the orchestration for anti-HIV CD8 T cell responses. These results provide further
support for the ongoing studies of the effects of REMUNE on viral load,`` Dr. Moss commented.

The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based
therapies to induce specific T-cell responses for the treatment of HIV and autoimmune diseases. In addition, the Company is
working on cancer vaccines and gene therapy.

NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news
releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension
434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site:
http://www.imnr.com.

This news release contains forward-looking statements. Actual results could vary materially from those expected due to a
variety of risk factors, including, but not limited to, whether additional clinical trials will be successfully concluded and whether
REMUNE will be approved for marketing or be successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended
December 31, 1998 and subsequent Forms 10-Q. The Company undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation.

SOURCE: The Immune Response Corporation

[SkyRocket]

IMNR ist eine meiner grössten Biotech-Positionen. Die Meldung heute wird für deutlich steigende Kurse sorgen - auf ISLAND bereits bei 18 Dollar.

Das Allzeithoch bei 60 ist das große Ziel - ich denke das werden wir noch übertreffen.

Dabeibleiben, denn inn ist wer drin ist.

Good luck

SkyRocket